{
  "report_header": {
    "analysis_date": "2026-02-01",
    "stock_code": "069620",
    "stock_name": "대웅제약"
  },
  "investment_summary": {
    "rating": "SELL",
    "target_price": 50000,
    "current_price": 168900,
    "upside_pct": -70.4,
    "conviction_score": 42.5
  },
  "agent_scores": [
    {
      "agent": "Financial Agent",
      "score": 50,
      "weight": 0.25,
      "weighted_score": 12.5,
      "rationale": "재무 데이터 없음 - 기본값 적용"
    },
    {
      "agent": "Valuation Agent",
      "score": 10.0,
      "weight": 0.2,
      "weighted_score": 2.0,
      "rationale": "고평가 (목표가: 50,000원, 상승여력: -70.4%)"
    },
    {
      "agent": "Technical Agent",
      "score": 50,
      "weight": 0.15,
      "weighted_score": 7.5,
      "rationale": "등락률: -0.82%"
    },
    {
      "agent": "Industry Agent",
      "score": 60,
      "weight": 0.15,
      "weighted_score": 9.0,
      "rationale": "업종 분석 - 기본값 적용"
    },
    {
      "agent": "Risk Agent",
      "score": 40,
      "weight": 0.15,
      "weighted_score": 6.0,
      "rationale": "위험 평가 기반"
    },
    {
      "agent": "Sentiment Agent",
      "score": 55,
      "weight": 0.1,
      "weighted_score": 5.5,
      "rationale": "심리 분석 - 기본값 적용"
    }
  ],
  "valuation": {
    "per": 78.56,
    "pbr": 2.45,
    "target_price": 50000
  },
  "risk_assessment": {
    "level": "MEDIUM",
    "factors": [
      "고평가 위험 (PER > 30)"
    ]
  },
  "summary": "대웅제약(069620)에 대해 SELL 의견을 제시합니다. Conviction Score 42.5/100으로 목표가 50,000원(상승여력 -70.4%)을 설정했습니다."
}